نتائج البحث

Enhancement of radiation therapy by indoleamine 2,3 dioxygenase 1 inhibition through multimodal mechanisms.

• Authors : Nozawa H; Department of Surgical Oncology, The University of Tokyo, 7-3-1 Hongo, Bunkyo-Ku, Tokyo, 113-8655, Japan. .; Taira T

Subjects: Kynurenine*/Kynurenine*/Kynurenine*/metabolism ; Colonic Neoplasms*/Colonic Neoplasms*/Colonic Neoplasms*/drug therapy ; Colonic Neoplasms*/Colonic Neoplasms*/Colonic Neoplasms*/radiotherapy

• Source: BMC cancer [BMC Cancer] 2023 Jan 18; Vol. 23 (1), pp. 62. Date of Electronic Publication: 2023 Jan 18.Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407

تفاصيل العنوان

AT-0174, a novel dual IDO1/TDO2 enzyme inhibitor, synergises with temozolomide to improve survival in an orthotopic mouse model of glioblastoma

• Authors : Michael J. Bickerdike; Imane Nafia; Alban Bessede

Subjects: IDO1; TDO2; Glioblastoma

• Source: BMC Cancer, Vol 24, Iss 1, Pp 1-15 (2024)

تفاصيل العنوان

Cancer-associated fibroblasts strengthen cell proliferation and EGFR TKIs resistance through aryl hydrocarbon receptor dependent signals in non-small cell lung cancer

• Authors : Hao Feng; Boxiong Cao; Xuan Peng

Subjects: Cancer-associated fibroblasts; EGFR TKIs resistance; Kynurenine

• Source: BMC Cancer, Vol 22, Iss 1, Pp 1-9 (2022)

تفاصيل العنوان

Tryptophan metabolism induced by TDO2 promotes prostatic cancer chemotherapy resistance in a AhR/c-Myc dependent manner

• Authors : Fan Li; Zhenyu Zhao; Zongbiao Zhang

Subjects: Tryptophan metabolism; Kynurenine; AhR

• Source: BMC Cancer, Vol 21, Iss 1, Pp 1-11 (2021)

تفاصيل العنوان

Tryptophan metabolism induced by TDO2 promotes prostatic cancer chemotherapy resistance in a AhR/c-Myc dependent manner.

• Authors : Li F; Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.; Zhao Z

Subjects: Drug Resistance, Neoplasm*/Drug Resistance, Neoplasm*/Drug Resistance, Neoplasm*/drug effects; Indoleamine-Pyrrole 2,3,-Dioxygenase/Indoleamine-Pyrrole 2,3,-Dioxygenase/Indoleamine-Pyrrole 2,3,-Dioxygenase/*metabolism ; Prostatic Neoplasms/Prostatic Neoplasms/Prostatic Neoplasms/*drug therapy

• Source: BMC cancer [BMC Cancer] 2021 Oct 17; Vol. 21 (1), pp. 1112. Date of Electronic Publication: 2021 Oct 17.Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407

تفاصيل العنوان

Epacadostat plus pembrolizumab versus placebo plus pembrolizumab for advanced urothelial carcinoma: results from the randomized phase III ECHO-303/KEYNOTE-698 study.

• Authors : Cicin, Irfan¹ (AUTHOR) ; Plimack, Elizabeth R.² (AUTHOR); Gurney, Howard³ (AUTHOR)

• Source: BMC Cancer. 7/25/2024, Vol. 23 Issue 1, p1-11. 11p.

تفاصيل العنوان

Pembrolizumab plus epacadostat in patients with recurrent/metastatic head and neck squamous cell carcinoma (KEYNOTE-669/ECHO-304): a phase 3, randomized, open-label study.

• Authors : Cho, Byoung Chul^1,2 (AUTHOR) ; Braña, Irene³ (AUTHOR); Cirauqui, Beatriz⁴ (AUTHOR)

• Source: BMC Cancer. 7/25/2024, Vol. 23 Issue 1, p1-12. 12p.

تفاصيل العنوان

Epacadostat plus pembrolizumab versus placebo plus pembrolizumab as first-line treatment for metastatic non-small cell lung cancer with high levels of programmed death-ligand 1: a randomized, double-blind phase 2 study.

• Authors : Tokito, Takaaki¹ (AUTHOR) ; Kolesnik, Oleksii² (AUTHOR); Sørensen, Jens³ (AUTHOR)

• Source: BMC Cancer. 7/25/2024, Vol. 23 Issue 1, p1-11. 11p.

تفاصيل العنوان

Pembrolizumab plus either epacadostat or placebo for cisplatin-ineligible urothelial carcinoma: results from the ECHO-307/KEYNOTE-672 study.

• Authors : Necchi, Andrea^1,2 (AUTHOR) ; Van der Heijden, Michiel S.³ (AUTHOR); Trukhin, Dmytro⁴ (AUTHOR)

• Source: BMC Cancer. 7/25/2024, Vol. 23 Issue 1, p1-11. 11p.

تفاصيل العنوان

Pembrolizumab with platinum-based chemotherapy with or without epacadostat as first-line treatment for metastatic non-small cell lung cancer: a randomized, partially double-blind, placebo-controlled phase II study.

• Authors : Boyer, Michael¹ (AUTHOR) ; Hui, Rina² (AUTHOR); Urban, Damien³ (AUTHOR)

• Source: BMC Cancer. 7/25/2024, Vol. 23 Issue 1, p1-12. 12p.

تفاصيل العنوان